Clinical Trials

36 enrolled

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT06347068 2026-04-22

Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

Phase 1 Recruiting

42 enrolled

Breast Neoplasms, Recurrence, Triple Negative Breast Neoplasms

NCT07069595 2026-04-22

PREDICT-RD

78 enrolled

Phase EARLY_PHASE1 Active not recruiting

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT02744053 2026-04-21

DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer

96 enrolled

Triple Negative Breast Neoplasms

NCT02957968 2026-04-21

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

46 enrolled 21 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07378306 2026-04-21

FACT-TN

80 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03366844 2026-04-20

Breast Cancer Study of Preoperative Pembrolizumab + Radiation

66 enrolled 16 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05491226 2026-04-20

Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation

35 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06134375 2026-04-20

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

Phase 1/2 Recruiting

204 enrolled

Phase 2 Not yet recruiting

Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT07015853 2026-04-20

ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation

34 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07525869 2026-04-20

An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC Regimen Following Paclitaxel and Carboplatin as Neoadjuvant Therapy

Phase NA Recruiting

40 enrolled

Triple Negative Breast Neoplasms

NCT03971409 2026-04-17

InCITe

145 enrolled

Phase 1 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05081492 2026-04-17

CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer

9 enrolled

Triple Negative Breast Neoplasms

NCT05570253 2026-04-17

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

55 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06492759 2026-04-17

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

29 enrolled

Triple Negative Breast Neoplasms

NCT04085276 2026-04-16

TORCHLIGHT

Phase 3 Completed

531 enrolled

Triple Negative Breast Neoplasms

NCT05749588 2026-04-16

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

120 enrolled

Triple Negative Breast Neoplasms

NCT06681064 2026-04-16

BELIEVE

Recruiting

500 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07011654 2026-04-16

Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

Phase 1/2 Recruiting

31 enrolled

Triple Negative Breast Neoplasms

NCT02876107 2026-04-15

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

42 enrolled

Breast Neoplasms, Edema, Erythema, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07045311 2026-04-15

JS207 Combination Therapy in Triple-negative Breast Cancer

80 enrolled

Triple Negative Breast Neoplasms

NCT04677816 2026-04-14

Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients

50 enrolled

Phase 2 Not yet recruiting

Vitamin D Deficiency, Triple Negative Breast Neoplasms

NCT07527819 2026-04-14

FERTILE

Not yet recruiting

75 enrolled

BreastGynecologic

Inflammation, Primary Ovarian Insufficiency, Triple Negative Breast Neoplasms

NCT07528768 2026-04-14

Gemcitabine vs Paclitaxel in Caribbean Women of African Ancestry With Metastatic Triple-Negative Breast Cancer

750 enrolled

Triple Negative Breast Neoplasms

NCT04768426 2026-04-13

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

40 enrolled

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT07340541 2026-04-13

EVOLVE-BDT

700 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07523789 2026-04-13

Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC

Not yet recruiting

201 enrolled

Phase NA Not yet recruiting

Triple Negative Breast Neoplasms

NCT07513311 2026-04-09

RESTORE

75 enrolled

Triple Negative Breast Neoplasms

NCT06649331 2026-04-08

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

160 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06604858 2026-04-07

TELESCOPE

31 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07078604 2026-04-07

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

20 enrolled

Triple Negative Breast Neoplasms

NCT04360941 2026-04-06

PAveMenT

Phase 1 Recruiting

45 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05660083 2026-04-03

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

36 enrolled

Phase 1 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06878248 2026-04-03

A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer

20 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07509515 2026-04-03

QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC.

60 enrolled

Triple Negative Breast Neoplasms

NCT04877821 2026-04-02

NeoSACT

Phase 2 Completed

29 enrolled

Triple Negative Breast Neoplasms

NCT06358573 2026-04-02

Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK

61 enrolled

Triple Negative Breast Neoplasms

NCT07017673 2026-04-02

Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

34 enrolled

Triple Negative Breast Neoplasms

NCT05809752 2026-04-01

A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)

Phase 1 Recruiting

18 enrolled

Meningeal Neoplasms, Triple Negative Breast Neoplasms

NCT06365788 2026-04-01

ABBICAR

53 enrolled

Phase EARLY_PHASE1 Recruiting

Bulbo-Spinal Atrophy, X-Linked, Triple Negative Breast Neoplasms

NCT06435351 2026-04-01

Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy

16 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06768931 2026-04-01

Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer

192 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01525966 2026-03-30

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer

67 enrolled 12 charts

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03586297 2026-03-27

Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer

Completed

49 enrolled

Triple Negative Breast Neoplasms

NCT06396754 2026-03-27

AIDOBE

Not yet recruiting

50 enrolled

Phase EARLY_PHASE1 Recruiting

Triple Negative Breast Neoplasms

NCT06586047 2026-03-27

Breast Cancer PSMA PET

30 enrolled

Phase NA Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07498400 2026-03-27

Exemption of SLNB After Neoadjuvant Therapy for Triple-negative and Her2-positive Breast Cancer

216 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05806060 2026-03-25

BCTOP-T-M01

Phase 3 Recruiting

134 enrolled

Triple Negative Breast Neoplasms

NCT02422498 2026-03-24

Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy

49 enrolled 8 charts